By Kamal Choudhury and Michael Erman March 6 (Reuters) - The controversial head of the U.S. Food and Drug Administration's vaccines and biologics unit, Dr. Vinay Prasad, will leave the agency at the ...

Vinay Prasad, director of the Center for Biologics Evaluation and Research, will leave the FDA at the end of April, an agency ...

The End the Vaccine Carveout Act would expose vaccine makers to lawsuits that once drove companies out of the industry.

Lantern announced partnerships with Novant Health and EmergeOrtho as part of its ongoing collaboration with the North Carolina State Health Plan. Nanox is collaborating with three new partners to ...

The Food and Drug Administration’s vaccine chief, Dr. Vinay Prasad, will depart the agency next month, an FDA spokesperson ...

Dr. Vinay Prasad, the US Food and Drug Administration’s head of vaccines and biologic medicines, will leave the agency at the end of April, a spokesperson confirmed to CNN on Friday.

Dr. Vinay Prasad will depart in April, after a year leading the division that approves vaccines and biotech drugs.

The Food and Drug Administration’s controversial vaccine chief, Dr. Vinay Prasad, is once again leaving the agency.

Investors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S.

Vinay Prasad, the top regulator overseeing vaccines and complex treatments for difficult diseases, had previously lost his job in July before getting it back less than two weeks later.

Dr. Vinay Prasad drew criticism for decisions that overrode agency scientists and rejected potential drugs. Dr. Vinay Prasad, ...

Lots of people are talking about peptides. But what are they? Here’s a quick primer on the health trend and what we know about peptides’ safety.